Table 3. Oxylipin concentrations in serum (nM).

Baseline (B), Placebo supplement (P) and ω-3 supplement (ω-3)

Class	PUFA	Oxylipin	Baseline (B)		Placebo supplement (P)		ω-3 supplement (ω-3)		p-values			Fold Change [Cω-3]/[CP]1
			Av2	CV3	Av	CV	Av	CV	B/P	B/ω-3	P/ω-3	Av	CV
ω-3	ALA	9-HOTrE	0.71	86	0.71	116	0.53	50	9.9E-01	1.7E-01	1.9E-01	1.0	57
		13-HOTrE	0.80	90	0.74	111	0.51	52	8.4E-01	7.8E-02	8.8E-02	0.9	47
		15(16)-EpODE	3.9	83	3.7	115	2.4	75	9.1E-01	6.8E-02	3.2E-02	0.8	52
		15,16-DiHODE	7.1	47	8.7	78	6.2	54	3.4E-01	2.9E-01	1.4E-02	0.8	32
		Sum (n=4)	13	53	14	90	10	54	6.6E-01	1.2E-01	2.2E-02	0.8	33
	EPA	12-HEPE	2.4	291	0.55	87	6.9	188	2.0E-01	1.3E-01	2.2E-02	27	228
		15-HEPE	0.07	129	0.10	114	0.56	88	3.2E-01	1.3E-05	2.4E-05	17	112
		11,12-DiHETE	0.04	83	0.05	103	0.22	59	2.7E-01	1.1E-07	2.6E-07	6.1	68
		14,15-DiHETE	0.07	60	0.09	87	0.36	55	3.7E-01	6.5E-08	2.2E-07	4.9	58
		17,18-DiHETE	0.47	48	0.56	80	2.2	59	3.9E-01	3.9E-07	5.1E-07	4.5	58
		Sum (n=5)	3.1	236	1.3	73	10.2	141	2.6E-01	3.1E-02	5.1E-03	9.0	124
	DHA	10(11)-EpDPE	0.25	74	0.24	111	0.47	77	9.2E-01	4.2E-03	7.2E-03	2.5	58
		4,5-DiHDPE	0.79	79	0.91	75	2.0	57	5.0E-01	1.5E-05	4.2E-05	2.7	48
		10,11-DiHDPE	0.19	71	0.24	154	0.38	55	5.2E-01	2.2E-05	8.1E-02	2.4	52
		13,14-DiHDPE	0.22	63	0.23	76	0.38	41	8.0E-01	9.8E-06	2.6E-04	2.0	41
		16,17-DiHDPE	0.30	49	0.33	76	0.50	40	6.0E-01	1.6E-05	4.3E-03	1.7	38
		Sum (n=5)	1.7	65	1.9	85	3.7	49	6.1E-01	4.6E-06	1.8E-04	2.3	39
ω-6	LA	9,12,13-TriHOME	3.5	67	3.3	56	3.2	55	7.5E-01	6.3E-01	8.9E-01	1.2	52
		9,10,13-TriHOME	1.7	60	1.6	59	1.6	55	7.0E-01	8.0E-01	8.9E-01	1.3	63
		9-HODE	13	81	13	103	9	43	9.7E-01	1.2E-01	1.1E-01	0.9	46
		13-HODE	23	79	23	83	17	49	9.3E-01	5.0E-02	5.8E-02	0.9	42
		9-KODE	2.9	122	2.2	153	1.9	104	5.2E-01	2.0E-01	6.5E-01	1.5	87
		9,10-DiHOME	3.7	73	4.5	102	2.5	52	4.4E-01	3.3E-02	2.2E-02	0.8	70
		12,13-DiHOME	6.8	61	7.6	80	5.0	46	5.9E-01	5.1E-02	1.8E-02	0.8	53
		9(10)-EpOME	4.1	101	3.2	125	2.4	99	4.2E-01	9.1E-02	3.4E-01	1.1	79
		12(13)-EpOME	6.1	93	4.6	91	3.5	76	2.9E-01	5.0E-02	1.8E-02	1.0	67
		Sum (n=9)	65	68	63	86	46	40	8.8E-01	3.6E-02	7.8E-02	0.9	44
	DGLA	15-HETrE	0.67	100	0.54	62	0.46	45	3.8E-01	7.5E-02	1.4E-01	0.9	43
		Sum (n=1)	0.67	100	0.54	62	0.46	45	3.8E-01	7.5E-02	1.4E-01	0.9	42
	AA	PGE2	0,34	251	0.06	108	0.16	156	1.2E-01	3.1E-01	9.0E-02	6.2	233
		TXB2	3.1	139	1.1	69	1.4	127	3.1E-02	7.7E-02	3.8E-01	2.1	156
		5-HETE	1.7	103	1.2	78	1.1	45	2.6E-01	7.1E-02	6.5E-01	1.2	50
		8-HETE	0.55	235	0.23	154	0.31	87	2.5E-01	3.3E-01	3.3E-01	9.1	179
		11-HETE	0.77	200	0.29	100	0.38	87	1.4E-01	1.7E-01	2.9E-01	3.0	162
		12-HETE	43	168	11	93	17	144	4.1E-02	9.3E-02	2.9E-01	2.8	163
		15-HETE	2.0	129	1.3	52	1.3	45	2.0E-01	1.3E-01	7.4E-01	1.1	44
		12-KETE	4.0	154	1.7	81	3.3	152	8.7E-02	2.9E-01	1.5E-01	6.1	318
		15-KETE	0.39	230	0.15	130	0.25	102	2.1E-01	4.2E-01	8.7E-02	2.9	93
		5(6)-EpETrE	0.51	89	0.38	50	0.34	85	1.7E-01	8.7E-02	5.5E-01	1.0	82
		8(9)-EpETrE	0.37	94	0.27	90	0.22	101	2.2E-01	7.3E-02	4.8E-01	1.2	97
		11(12)-EpETrE	0.43	134	0.29	97	0.29	130	2.5E-01	2.6E-01	9.6E-01	1.5	103
		14(15)-EpETrE	0.48	140	0.32	82	0.38	105	2.8E-01	5.0E-01	5.8E-01	1.5	81
		5(6)-DiHETrE	0.29	65	0.26	63	0.19	40	5.1E-01	2.4E-03	3.3E-02	0.8	38
		8(9)-DiHETrE	0.31	74	0.33	101	0.22	45	8.2E-01	1.7E-02	9.3E-02	0.8	38
		11(12)-DiHETrE	0.75	62	0.70	70	0.51	30	7.3E-01	4.0E-03	6.3E-02	0.9	33
		14(15)-DiHETrE	0.91	67	0.91	81	0.64	26	9.8E-01	1.3E-02	6.6E-02	0.8	29
		Sum (n=17)	60	153	20	64	28	106	4.7E-02	8.7E-02	2.8E-01	1.8	121
		Sum (n-15)4	13	109	7.8	63	7.7	45	1.1E-01	5.1E-02	9.4E-01	1.2	53

¹The fold change in oxylipin serum concentrations (C) comparing subjects following ω-3 supplementation (ω-3) and placebo supplementation (P), i.e., [C_ω-3]/[C_P]

²Average

³Coefficient of variance

⁴Excluding 12-HETE and 12-KETE